Wiedemann B, Heisig P
Pharmaceutical Microbiology, University of Bonn, Germany.
J Antimicrob Chemother. 1997 Dec;40 Suppl A:19-25. doi: 10.1093/jac/40.suppl_1.19.
Grepafloxacin has an extremely broad spectrum of activity. Its activity against Gram-positive bacteria exceeds that of currently available quinolones. Grepafloxacin-resistant mutants seem to occur less frequently than ciprofloxacin- or ofloxacin-resistant mutants, and the increase in MIC against the former mutants is less than that of the latter. This applies only to the relative differences (in dilution steps); the absolute values are similar. Grepafloxacin kills Gram-positive bacteria at concentrations little above the MIC. Its pharmacodynamic profile against pneumococci is promising, favouring use of this drug for respiratory tract infections.
格帕沙星具有极广的抗菌谱。其对革兰氏阳性菌的活性超过了目前可用的喹诺酮类药物。与环丙沙星或氧氟沙星耐药突变体相比,格帕沙星耐药突变体似乎出现的频率更低,并且对前一种突变体的最低抑菌浓度(MIC)增加幅度小于后一种。这仅适用于相对差异(稀释步骤中的差异);绝对值相似。格帕沙星在略高于MIC的浓度下就能杀死革兰氏阳性菌。其针对肺炎球菌的药效学特征很有前景,有利于将该药物用于呼吸道感染。